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Abstract: Asian Indians have a high predisposition to metabolic syndrome (MS) and coronary 
artery disease (CAD). The present study aimed to estimate MS prevalence in 531 Asian Indian 
families comprising of 2318 individuals. Anthropometrics and lipid proﬁ  le were assessed. MS 
prevalence was estimated using standard Adult Treatment Panel III (ATP-III) and World Health 
Organisation (WHO) criteria and modiﬁ  ed deﬁ  nitions which included lowered cut-offs for 
waist circumference (WC) ( 90 cm for men and  80 cm for women], body mass index (BMI) 
( 23 kg/m2) and impaired fasting glucose (IFG) levels. ATP-III criteria identiﬁ  ed a signiﬁ  cantly 
higher proportion of people with MS (N = 933; 40.3%) compared with WHO (N = 708; 30.6%; 
p   0.0001) while modiﬁ  ed ATP-III showed maximum gain in percent prevalence among the 
revised criteria (17.3%; p = 0.0056). The IDF criteria identiﬁ  ed similar proportion of subjects 
with MS (N = 809; 34.9%) as the revised WHO criteria (N = 792; 34.2%). The number of MS 
subjects was highest in the 50–59 years age group. MS was diagnosed a decade earlier in unaf-
fected subjects compared with those with CAD/diabetes using the modiﬁ  ed MS criteria. WC 
correlated signiﬁ  cantly with BMI and waist–hip ratio (WHR) (p = 0.000). Among MS compo-
nents, high density lipoprotein cholesterol and BMI contributed signiﬁ  cantly in males (71.4% 
and 85.9%) and females (86.8% and 88.8%), respectively. The higher percentage contribution of 
WC among males and WHR among females indicates the inﬂ  uence of gynecoid/android pelvis 
on WHR measures. In conclusion, the revision of deﬁ  nition criteria for MS with lowered cut-offs 
for WC and BMI is critical for the accurate assessment of MS among Asian Indians.
Introduction
Metabolic syndrome (MS) refers to a cluster of features namely central obesity, insulin 
resistance, dyslipidemia, and hypertension (Reaven 1988). Numerous studies have 
been conducted worldwide on the prevalence of MS across different ethnic groups 
(Misra et al 2002; Al-Lawati et al 2003; Yong-Woo 2003; Kuninori et al 2005), the 
correlation between the components of the syndrome (Young et al 2004; Ang et al 
2005) and increased incidence of cardiovascular diseases (CVD) (Anand et al 2003; 
Coopan 2005). Asian Indians have long been considered to be a “high-risk population” 
for both MS and CVD, which has instigated a number of studies on Indians living in 
India (Ramachandran et al 1998; Misra et al 2005) and abroad (Hughes et al 1997; 
Tan et al 2004; Shah et al 2005).
The National Cholesterol Education Program–Adult Treatment Panel III 
(NCEP–ATP-III 2001) and World Health Organization (WHO 1999) have laid down 
guidelines to deﬁ  ne MS and both deﬁ  nitions have been widely applied to different 
populations under study. While Insulin resistance has been the pivotal feature in the 
WHO criteria, waist circumference (WC) rather than body mass index (BMI) has been 
the differentiating aspect of MS deﬁ  nition in the ATP-III panel. The International Vascular Health and Risk Management 2008:4(1) 190
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Diabetes Federation (IDF) proposed a slight modiﬁ  cation 
in the ATP-III deﬁ  nition in 2005 (Albert et al 2005) where 
presence of abdominal obesity was considered mandatory 
for MS diagnosis. The American Heart Association/National 
Heart, Lung and Blood Institute (AHA/NHLBI) supports the 
widely used ATP-III criteria except for a lowering of thresh-
old for impaired fasting glucose (IFG) from 110 to 100 mg/dL 
(Grundy 2005) as recommended by IDF. In spite of the vari-
ous criteria devised for MS diagnosis, most studies agree that 
the prevalence of MS in Asian Indians is underrepresented 
when ATP-III or WHO criteria are employed, considering 
the high propensity of this ethnic group to develop MS and 
its various co-morbidities (Misra et al 2005). It is well known 
that Asian Indians have a smaller build and excess body fat 
with predominant abdominal adiposity as compared with 
Caucasians. To this effect, the WHO has recognized the need 
for a population-speciﬁ  c modiﬁ  cation of anthropometric 
measures. The recommended lower BMI cut-off for deﬁ  n-
ing ‘overweight’ in Asian Indians is 23 kg/m2 (WHO 2004), 
modiﬁ  ed WC measures is  94 cm and  80 cm (Misra et al 
2005) and a waist–hip ratio (WHR) of 0.89 and 0.81 for men 
and women, respectively (Snehalatha 2003). These modiﬁ  ed 
cut-offs have been applied when studying Asian Indians by 
several investigators (Misra et al 2005; Tan et al 2005; Tillin 
et al 2005; Heng et al 2006).
In this context, the aim of this study was to assess the 
prevalence of MS as deﬁ  ned by the standard ATP-III and 
WHO criteria and the modiﬁ  ed criteria, and to look for dif-
ferences between the various components constituting MS 
in subjects with and without the syndrome in a high-risk 
cohort of families with premature onset of coronary artery 
disease (CAD).
Materials and methods
Subjects
The current study has been conducted on a cohort enrolled 
into the Indian Atherosclerosis Research Study (IARS), by 
the Thrombosis Research Institute-India (TRI-India). IARS is 
an on-going family based genetic epidemiological study, with 
an aim to investigate the genetic factors associated with CAD 
along with their interaction with traditional and novel risk 
factors in a cohort of Asian Indian population in their home 
country. The IARS families were enrolled from two cities, 
Bangalore in South India and Mumbai in Western India from 
March 2004 – July 2005. Subjects were ascertained through 
a proband (males  60 years; females  65 years at onset of 
CAD) admitted to Narayana Hrudayalaya, a multispecialty 
hospital and other cardiac care hospitals in Bangalore and to 
the Asian Heart Institute in Mumbai for undergoing treatment 
for CAD and its complications. Only probands with a posi-
tive family history of CAD were enrolled into the study. A 
detailed pedigree of the families of each proband was drawn 
and affected and unaffected family members over 18 years 
age were subsequently enrolled into the study. None of the 
participants had concomitant or past major illness. In total, 
ﬁ  ve hundred and thirty one families comprising of 2316 
individuals, 1355 males and 961 females were enrolled, with 
a mean of 4.37 individuals per family.
A detailed case record form containing information 
on demographics, anthropometry and medical history of 
diabetes, hypertension and CVD was recorded for all the 
participants. General physical examination along with 
vital parameters was performed. Relevant information was 
obtained by personal interviews and through medical records 
available with the subjects and/or from the hospital records. 
Prevalence of diabetes (DM), hypertension (HTN), and CVD 
was ascertained based on self-report of physician’s diagnosis 
and/or use of prescription medications along with medical 
records of therapeutics. Additional information on diabetic 
status was obtained from IFG levels. All participants gave 
their written informed consent to participate in the study that 
was approved by the local Ethics Committee.
Clinical proﬁ  le and anthropometrics
Height, weight, waist and hip circumference and blood pres-
sure (BP) was measured for each participant. BMI was calcu-
lated as a ratio of weight in Kg to the height in meter2.
Laboratory assays
Venous blood was collected in evacuated tubes after an 
overnight fast of 12 to 14 hours (Vacuette®, Greiner Bio-One 
GmbH, Vienna, Austria). Serum, EDTA, and citrate plasma 
samples were separated by centrifugation within 2 hours of 
sampling and aliquots were preserved at −80 °C until analysis. 
Samples from Mumbai were stored at −20 °C until dispatch 
to TRI labs in Bangalore for analysis. Fasting venous blood 
sugar was assayed using a Glucometer (Bayer Diagnostics, 
Newbury, UK). Serum triglyceride (TG) was estimated using 
reagents, standards and controls from Randox Laboratories 
Ltd., Antrim, UK. Estimation of high density lipoprotein 
cholesterol (HDL-C) levels was carried out by the phospho-
tungstate method using precipitating agents and buffer from 
Bayer Diagnostics, control from Randox Labs and standards 
from Dade-Behring Limited, UK. All lipid assays were car-
ried out on Cobas-Fara II Clinical Chemistry Auto analyzer 
(F. Hoffman La Roche Ltd., Basel, Switzerland).Vascular Health and Risk Management 2008:4(1) 191
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Candidate metabolic syndrome 
deﬁ  nitions
Prevalence of metabolic syndrome in the cohort was assessed 
on the basis of the following criteria:
A) The 2001 NCEP–ATP-III guidelines, wherein presence 
of any three of the following traits in the same individual 
would meet the criteria for MS:
  1.    Abdominal obesity as deﬁ  ned by WC  102 cm 
(40 in) in men and  88 cm (35 in) in women;
 2.  Serum  TG   150 mg/dL (1.7 mml/L);
 3.    HDL-C   40 mg/dl in men (1.03 mmol/L) and 
 50 mg/dl (1.29mmol/L) in women;
  4.  Blood pressure of  130/85 mmHg
  5.    Fasting blood glucose level of  110 mg/dL 
(6.1 mmol/L).
B)  The WHO criteria emphasized insulin resistance, identi-
ﬁ  ed by type 2 diabetes mellitus or an impaired fasting 
glucose of  110 mg/dl, in addition to the following 
features:
 1.    WHR  of   0.9 in men,  0.85 in women or a BMI 
 30 Kg/m2.
 2.  Hypertriglyceridemia  with  TG 150mg/dl;
 3.    HDL-C   35 mg/dl for men and  39 mg/dl for 
women;
 4.    High  BP   140/90 mm Hg or documented evidence 
of anti-hypertensive therapy.
  Presence of Microalbuminuria was not assessed in our 
cohort.
C)  IDF (International Diabetic Federation 2005): Abdominal 
obesity as deﬁ  ned by WC  94 cm for men and  80 cm 
is a mandatory feature of this deﬁ  nition and is speciﬁ  c to 
Asians. In addition, any of the two features as deﬁ  ned in 
ATP-III constitute MS by this criteria. IFG cut-off level 
was  100 mg/dL.
D) Modiﬁ  ed ATP-III-1 [MS1]: WC cutoffs  90 cm for 
men and  80 cm for women. Criteria from 2 to 5 
were unchanged as per the NCEP ATP-III description 
above.
E) Modiﬁ  ed ATP-III-2 [MS2]: BMI cutoff at  23 Kg/m2 
in addition to the criteria used in MS1.
F) Modiﬁ  ed WHO [MS3]: The deﬁ  nitions were same as for 
the WHO criteria except for WHR of  0.89 in males and 
 0.81 in females and a BMI  23 kg/m.2
Statistical analysis
Results are expressed as mean ± standard deviation for the 
continuous variables. Chi Square test with Yates correction 
was employed to analyze the differences in the prevalence of 
MS as identiﬁ  ed using candidate deﬁ  nitions. Pearson’s partial 
correlation was carried out to investigate the inter-relationship 
amongst the various MS components after adjustment for 
gender and age. Values were log-transformed to normal-
ize distribution. Student T-test was employed to evaluate 
the difference in means levels of various markers between 
those with and without MS. For statistical comparison of the 
continuous variables, ANCOVA was used with adjustment 
for age, gender, BMI and smoking. Generalized estimating 
equation (GEE) was applied to study the signiﬁ  cant trait dif-
ferences between MS and non-MS subjects using STATA 
version 9.0 software. Since observations within families are 
not independent but correlated, GEE adjusts for the effect of 
familial relationship and subsequently looks for signiﬁ  cant 
relationship between traits in the MS and non-MS groups. 
Families were assumed to have binomial distribution for 
discrete vairables and Gaussian distribution for continuous 
variables under the assumption of unstructured correlation 
within families for any of the analysed traits. A nominal two-
sided p-value  0.05 was considered signiﬁ  cant. All statistical 
tests were computed on SPSS v10 software.
Results
Standard candidate deﬁ  nitions (ATP-III, WHO, IDF) and 
various adaptations therein (MS1, MS2, MS3) were applied 
to 2316 individuals enrolled into the IARS. Prevalence of 
MS based on various deﬁ  nitions is presented in Table 1. 
The number of people diagnosed with MS by the ATP-III 
criteria (N = 933) was signiﬁ  cantly higher than by the WHO 
criteria (N = 708; p   0.0001). Among the modiﬁ  ed ATP-
III criteria, MS2 that included revised cut offs for WC and 
BMI identiﬁ  ed maximum MS subjects (N = 1333). The IDF 
criteria identiﬁ  ed similar proportion of people with MS (N = 
809; 34.9%) as the modiﬁ  ed WHO criteria (MS3) (N = 792; 
34.2%). Maximum gain in MS diagnosis was observed in 
Table1 Prevalence of metabolic syndrome (MS) according to 
different deﬁ  nition criteria
MS Deﬁ  nition  N  Percent 
ATP-III 933  40.3 
WHO 708  30.6 
IDF 809  34.9
MS1 1187  51.3 
MS2 1333  57.6 
MS3 792  34.2 
Abbreviations: ATP-III, Adult Treatment Plan 111; WHO, World Health Organiza-
tion; IDF, International Diabetic Foundation; MS1, ATP-III deﬁ  nition modiﬁ  ed with 
respect to WC; MS2, MS1 + modiﬁ  ed BMI ( 23kg/m2); MS3, WHO deﬁ  nition modi-
ﬁ  ed with respect to WHR and BMI; BMI, body mass index; WC, waist circumfer-
ence; WHR, waist–hip ratio.Vascular Health and Risk Management 2008:4(1) 192
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the modiﬁ  ed ATP-III group (MS2) (17.3%) when compared 
with standard ATP-III guidelines. Analyses of percentage 
prevalence gain of MS by the modiﬁ  ed ATP-III criteria 
(MS1, MS2) and WHO criteria (MS3) revealed signiﬁ  cant 
gain (N = 400) by MS2 over MS3 (p = 0.0056) criteria.
Age and sex adjusted correlations of each MS component 
criteria among diabetic subjects in MS1 and MS3 groups are 
provided in Table 2. Insulin resistance is a mandatory criterion 
for the designation of MS accorded by MS3. Hence, in order 
to analyze comparable groups, only diabetics in the MS1 cat-
egory were considered for analysis. TG, HDL-C, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP) showed 
signiﬁ  cant correlation between the two groups whereas WC did 
not correlate with either WHR or BMI. HTN implies already 
diagnosed hypertensive individuals who are on medication.
Amongst males, MS prevalence increased proportionately 
after 30 years of age in all the deﬁ  nitions to reach a maximum 
in the 50–59 age group (Figure 1A). MS prevalence reduced 
after 60 yrs of age that approximated to the levels prevalent in 
the 18–29 age group. MSI and MS2 identiﬁ  ed higher number 
of younger people with MS (30–39 yrs) compared with the 
WHO and MS3 deﬁ  nitions. Amongst females, MS prevalence 
started to increase later than in the males (40 yrs onwards) and 
continued to remain high beyond 60 yrs of age, in contrast to 
our observation in males. Maximum prevalence was in the 
50–59 age group (Figure 1B). Overall, the WHO and MS3 
deﬁ  nitions diagnosed more males while the IDF criteria diag-
nosed more number of females with metabolic syndrome.
MS, NIDDM, and CVD
Seven hundred and seventy six individuals (33.5%) in the 
IARS cohort had cardiovascular disease (CVD) by the time 
of their recruitment, while noninsulin-dependent diabetes 
mellitus (NIDDM) was present in 1048 (45.3%) subjects. 
68.4% of subjects in the MS2 group were diabetic and had 
CVD compared with 30.3% of nondiabetics who had CVD. 
Only 17.2% of CVD affected people in our cohort were not 
diagnosed to have MS by the MS2 criteria. The mean ages 
of all CVD affected subjects either with or without MS2 
and/or NIDDM was very similar and were as follows: 57 ± 8 
years (CVD + MS2 + NIDDM), 54.7 ± 9 years (CVD + MS2 
- NIDDM) and 55 ± 11 years (CVD - MS2 - NIDDM) (MS2 
implies people diagnosed with MS as per MS2 deﬁ  nition). In 
comparison, MS3 also diagnosed a high proportion of people 
who had both CVD and MS and their mean age was 57.2 ± 8 
years. The MS2, MS3 and IDF criteria were able to diagnose 
MS in people without CVD in their fourth decade of life (MS2 
45.8 ± 12.7 years; MS3 47.6 ± 12.5 years; 45.57 ± 14.72).
Comparison of component risk factor for MS such as 
age, SBP, and DBP (p = 0.000), HTN, diabetes mellitus 
(DM), CVD (p   0.001), glucose fasting blood sugar (GFBS), 
WC, and BMI (p = 0.000) were signiﬁ  cantly higher in the 
MS group and continued to remain signiﬁ  cant after age and 
sex adjustment when compared with the non-MS group 
(Table 3). Results obtained from GEE showed similarity up 
to the third decimal place as compared to routine tests such 
as Chi-square for discrete variables and T-test, ANOVA, and 
binary logistic regression for continuous variables between 
MS and non-MS subjects implying that family relationship 
is not a confounding factor in this study.
Monocomponent analysis of MS traits across gender 
showed that HDL-C and BMI were signiﬁ  cant contributors 
in males (N = 562, 71.4%; N = 676, 85.9%) and females 
(N = 474, 86.81%; N = 485, 88.8%) respectively. WC was 
more signiﬁ  cant among females in MS2 (N = 480; 87.91%) 
group while WHR (N = 468, 91.8%) showed signiﬁ  cant 
contribution in males as per the MS3 deﬁ  nition, thus indi-
cating the inﬂ  uence of the gynecoid/android pelvis on WHR 
measures (Figure 2).
Discussion
Distinct clinical features and metabolic predispositions 
are frequently noted in people with abdominal adiposity, 
insulin resistance, dyslipidemia, and HTN. To simplify 
Table 2 Correlation of MS traits in diabetic subjects between 
MS1 and MS3 groups
MS1* / MS3# N  p  value  Mean  ± SD
WC1 (cm)  767    92.87 ± 9.6
WHR 3  767    0.93 ± 0.08
BMI 3 (kg/m2) 770   26.97  ± 4.5
WC 1/WHR 3  761  NS 
WC 1/BMI 3  764  NS 
TG 1(mg/dl)  780    167.03 ± 83.56
TG 3  780    167.48 ± 84.67
TG 1/TG 3  774  0.000 
HDL 1  780    40.01 ± 9.2
HDL 3  780    40.02 ± 9.6
HDL1/HDL 3  774  0.000 
SBP1 (mm/Hg)  776    129.07 ± 16.84
SBP 3  776    129.16 ± 17.13
SBP1/SBP 3  770  0.003 
DBP1 (mm/Hg)  776    82.10 ± 8.88
DBP 3  776    83.24 ± 9.02
DBP1/DBP 3  770  0.014 
HTN 1/HTN 3  774  0.026 
Notes: *Sufﬁ  x 1 in each variable pertains to the trait in MS1 group; #Sufﬁ  x 3 in 
each variable pertains to the trait in MS 3 group;
Abbreviations: WC, waist circumference; WHR, waist–hip ratio; BMI, body mass 
index; TG, triglyceride; HDL, high-density lipoprotein; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HTN, hypertension.Vascular Health and Risk Management 2008:4(1) 193
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the recognition of such a clustering, the WHO laid down 
deﬁ  nitive criteria (WHO 1999), followed by the MS deﬁ  ni-
tion of NCEP–ATP-III (ATP-III 2001) and IDF (Albert et al 
2005). The Center for Disease Control and Prevention and US 
Department of Health and Human Services have attributed 
a speciﬁ  c code to “dysmetabolic syndrome” (ICD #277.7) 
(CDC 2002) in the 9th revision in clinical classiﬁ  cation, thus 
bestowing it with an implicative dignity.
Asian Indians are a high-risk population with respect to 
diabetes mellitus and CVD and the numbers are consistently 
on the rise (Enas et al 1992; Enas and Senthilkumar 2001). 
It has long been doubted that the above standard deﬁ  nitions 
of MS under represents its prevalence in the Asian Indian 
community, thereby delaying the commencement of deﬁ  nite 
preventive and therapeutic efforts in many individuals. The 
results of various studies have appreciated ethnic varia-
tion in clinical measures and disease outcomes in different 
populations (Anand et al 2003; Tan et al 2004). Part of the 
problem lies in the cutoffs for obesity as deﬁ  ned by the 
WHO and ATP-III, which are not valid for Asian Indians. 
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Figure 1A Prevalence of MS in males across different age groups according to various MS deﬁ  nition criteria. B MS prevalence in females. Also included is data on IARS 
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This population is of smaller build, has high insulin resistance 
and a dysmetabolic adipocyte milieu at considerably lower 
BMI and abdominal adiposity as identiﬁ  ed by a large WC 
(Cooppan 2005). In the wake of ongoing debate and a lack 
of consensus, the WHO recognized the need for population 
speciﬁ  c cutoff deﬁ  nitions in order to make the diagnosis of 
MS more precise and modiﬁ  ed the BMI cutoff in Asians 
(WHO 2004). Also, the IDF (Albert et al 2005) published 
consensus cutoff for WC that are more ethnic-speciﬁ  c, based 
on the Chinese, Malay, and Asian Indian populations. In the 
present study, three candidate deﬁ  nitions were devised for 
MS by substituting the above modiﬁ  ed cutoffs for BMI and 
WC, as also the WHR in the ATP-III and WHO deﬁ  nitions 
while IDF criteria was independently assessed in this study. 
The various deﬁ  nitions were applied to a cohort with high-
risk for CAD where all participants had a family history of 
premature onset of CAD. MS prevalence was higher in our 
cohort in comparison to other studies. At baseline, ATP-III 
labeled a signiﬁ  cantly higher proportion of people with MS 
when compared with the WHO criteria. A consistent gain 
in MS diagnosis was achieved by applying the modiﬁ  ed 
deﬁ  nitions over the standard ones. Maximum gain was 
obtained in the MS2 group as deﬁ  ned by applying modiﬁ  ed 
WC and BMI over and above the MS1 deﬁ  nition, which 
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Figure 2 The percent contribution of individual components used in the deﬁ  nition of MS among males and females.
Table 3 Frequency and mean differences in cardiovascular risk factors between metabolic syndrome (MS)* and non-MS group
Risk  factor  MS     Non-MS    GEE 
 N  (%)  Mean  ± SD  N (%)  Mean ± SD  ‘p’ Value
Gender - male  787 (59.04)    567 (57.74)    0.536
Female  546 (40.96)    415 (42.26) 
Age 1324  (99.8)  50.23  ± 12.25 976  (100) 39.24  ± 15.41  0.000
DM  455 (34.21)    54 (5.53)    0.000
HTN  579 (43.47)    105 (10.74)    0.000
SBP  1327 (100)   128.69 ± 16.56  976 (100)  117.57 ± 12.75  0.000
DBP 1327(100)  83.59  ± 8.9  976 (100)  77.9 ± 8.14  0.000
GFBS 893  (67.3)  138.21  ± 56.83  658 (67.4)  103.01 ± 26.86  0.000
Smokers  178 (18.22)    308 (23.2)    0.004
CVD  578 (43.36)    198 (20.14)    0.000
WC 1319  (99.4)  92.16  ± 9.61  974 (99.8)  82.88 ± 11.32  0.000
BMI 1327  (100)  27.17  ± 4.28  974 (99.8)  23.74 ± 4.22  0.000
Note: MS* refers to modiﬁ  ed MS2 deﬁ  nition (Modiﬁ  ed ATP-III deﬁ  nition).
Abbreviations: DM, diabetes mellitus; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; GFBS, CVD, cardiovascular disease; WC, waist 
circumference; BMI, body mass index.Vascular Health and Risk Management 2008:4(1) 195
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used only a modiﬁ  cation in WC in its criteria. A comparable 
ﬁ  nding was reported using modiﬁ  ed ATP-III criteria for 
anthropometry, which included skin fold thickness measure-
ments in their candidate deﬁ  nition (Misra et al 2005). The 
IDF proposes that central obesity is an essential component 
of MS, while the American Heart Association/National Heart, 
Lung and Blood Institute (AHA/NHLBI) opines that it is an 
optional component similar to the other MS factors. Also, the 
IDF supports a modiﬁ  ed cut off in impaired fasting glucose 
(IFG) levels of  100 mg/dL as compared with  110 mg/DL 
set by other criteria. Lee and colleagues (2007) support the 
AHA/NHLBI proposal in their study on risk of ischemic 
heart disease (IHD) risk among healthy Asians.
Distribution of MS across various age groups showed a 
gradual increase in prevalence with advancing age in both 
males and females in our cohort with maximum prevalence in 
the 50–59 age group. Distribution of MS prevalence was simi-
lar across age groups in MS1, MS2, and IDF categories. Tan 
and colleagues (2004) reported a similar trend in prevalence. 
It is of interest to note that our study population was recruited 
through probands with premature CAD and the most vulner-
able age group for manifestation of CAD was around the same 
time as the peak prevalence of MS in this study, which was 
around 51.75 ± 8.62 years. In this context, early detection of 
MS would be of immense importance to deploy prophylactic 
measures against component risk factors of MS. The modiﬁ  ed 
ATP-III criteria [MS1 and MS2] were able to identify greater 
number of young people with MS [30–39 yrs] than the WHO 
criteria. Hence the above modiﬁ  cations do indicate their ability 
to identify the ‘high-risk subjects’ much earlier.
The NCEP deﬁ  nition is more ﬂ  exible as it can diagnose 
MS even in the absence of glucose intolerance, which in itself 
is a predisposition to dysmetabolic dyslipidemia, an obesity 
phenotype and a pro-inﬂ  ammatory status. The WHO criteria, 
on the other hand, mandate the presence of diabetes with the 
inclusion of microalbuminuria, which is not only a marker 
for renal disease, but also for CVD. By the time most patients 
receive a diagnosis of diabetes, they are more than likely to 
have developed micro- or macro-vascular disease (Enas et al 
1992). It can thus be expected that a greater proportion of 
the patients will have CVD, if MS is determined based on 
the WHO guidelines. This is reﬂ  ected by a signiﬁ  cant risk of 
development / progression of carotid atherosclerosis as noted 
in the prospective Bruneck study (Bonora et al 2003). Thus, 
there is a bias in prevalence in relation to this end point. In 
the IARS cohort, 68.4% of the CVD affected were diabetic. 
Employing the MS2 and MS3 criteria, those with MS but 
without CVD were identiﬁ  ed by the mid-forties, while CVD 
appeared to be incident a decade later in our cohort. Also, 
MS2 was successful in identifying 82.8% of CVD cases. A 
similar observation was made in the 4S and the AFCAPS-
TEXCAPS studies that estimated the prospective long-term 
relative risks of major cardiac events associated with MS 
after exclusion of DM (Girman et al 2004).
In order to analyze the association of various phenotypes 
with MS, identiﬁ  cation and selection of the best-suited 
deﬁ  nition was imperative for this study. To this end, it was 
hypothesized that any of the component factors that did not 
correlate between the candidate deﬁ  nitions was actually 
responsible for the gain that was observed in the MS diag-
nosis. Applying Pearson correlation to component factors of 
MS1 and MS3, all factors apart from the markers of adiposity, 
namely WC, WHR, and BMI, showed signiﬁ  cant correlation 
(Table 2) thus implying that only those factors that were 
modiﬁ  ed were responsible for the enhanced ‘pick-up’ rate. 
MS2 was therefore selected for further analysis in lieu of the 
maximum gain achieved in diagnosing MS.
Subjects with MS were on an average ten years older than 
those without the syndrome. Signiﬁ  cantly larger number of 
people with MS were hypertensive and diabetic with higher 
anthropometric parameters and incidence of CVD when 
compared with those without MS. BMI showed correlation 
with WC but not with WHR, which indicates that WC and 
BMI may be better predictors of MS when compared with 
WHR in Asian Indians. Kurpad and colleagues (2003) found 
similar correlation between WC and BMI and suggest that 
WC is a better marker of abdominal obesity than WHR.
The present study and previous related investigations sug-
gest many opportunities to prevent and retard the progression 
of CVD in this high-risk group, such as weight loss, dietary 
and lifestyle modiﬁ  cations (Enas and Senthilkumar 2001). 
This, in turn, would help to some extent in delaying the 
downstream progression into insulin resistance, hypertension 
and dyslipidemia. Also, control of conventional CVD risks 
is more effective when they are detected and arrested at an 
early developmental stage.
On the basis of this study and considering the prevalent 
socio-economic scenario in developing countries like India 
where limited resources are available to health providers 
and seekers alike, we would recommend the anthropometric 
evaluation of Asian Indians as a primary screening technique 
to identify metabolic syndrome. Only people with abnormal 
anthropometry could be subsequently subjected to various 
laboratory assays for conﬁ  rmation of diagnosis of metabolic 
syndrome. To this effect we found that by applying lowered 
cutoff for BMI and WC criteria alone, about 30% of the cases Vascular Health and Risk Management 2008:4(1) 196
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in the MS2 category missed MS diagnosis underlining the 
importance of abnormal anthropometry in the identiﬁ  cation of 
potential ‘high-risk’ MS subjects among Asian Indians.
In conclusion, prevalence of MS varies amongst ethnic 
groups. Asian Indians are high at risk for CVD, diabetes, and 
their predispositions. The criteria for deﬁ  ning MS in adult 
Asian Indians needs to be reassessed. Inclusion of modiﬁ  ed 
cut-offs of WC, BMI in the ATP-III deﬁ  nition, and WHR in 
the WHO deﬁ  nition yielded higher rates of MS identiﬁ  cation 
in our study. WC and BMI deﬁ  ne MS better, while WC is a 
preferable marker of abdominal adiposity. However, these 
ﬁ  ndings need further validation.
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